Akebia Therapeutics Inc. (NASDAQ:AKBA)’s traded shares stood at 2.93 million during the last session, with the company’s beta value hitting 0.91. At the close of trading, the stock’s price was $1.39, to imply a decrease of -0.71% or -$0.01 in intraday trading. The AKBA share’s 52-week high remains $2.48, putting it -78.42% down since that peak but still an impressive 57.55% since price per share fell to its 52-week low of $0.59. The company has a valuation of $291.02M, with an average of 4.78 million shares over the past 3 months.

Akebia Therapeutics Inc. (NASDAQ:AKBA) trade information

After registering a -0.71% downside in the last session, Akebia Therapeutics Inc. (AKBA) has traded red over the past five days. The stock hit a weekly high of 1.5500, dropping -0.71% in its intraday price action. The 5-day price performance for the stock is -10.90%, and -26.46% over 30 days. With these gigs, the year-to-date price performance is 12.10%.

Akebia Therapeutics Inc. (AKBA) estimates and forecasts

Looking at statistics comparing Akebia Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Akebia Therapeutics Inc. (AKBA) shares are 57.94% up over the last 6 months, with its year-to-date growth rate lower than industry average at 0.00% against 9.70%.

AKBA Dividends

Akebia Therapeutics Inc. has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Akebia Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.